GlassScriptPhysician profile
Marta E Terlecki
NPI 1881627461
$2,514.12
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.00 · 2020: $164 · 2021: $610 · 2022: $692 · 2023: $348 · 2024: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $599.54 | 2020-2024 | |
| Lilly USA, LLC | $590.25 | 2020-2024 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $314.05 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.40 | 2021-2024 | Jardiance |
| Amgen INC. | $95.81 | 2022 | |
| Genzyme Corporation | $90.00 | 2019 | |
| Xeris Pharmaceuticals, INC. | $87.66 | 2021-2024 | Recorlev, Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $76.94 | 2021-2022 | |
| Abbvie INC. | $71.62 | 2022-2024 | Synthroid |
| Dexcom, INC. | $48.12 | 2022-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $40.45 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.13 | 2022 | |
| Recordati_rare_diseases_inc. | $36.62 | 2024 | Signifor Lar, Isturisa |
| Radius Health, INC. | $23.13 | 2022 | |
| Pfizer INC. | $22.59 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $21.61 | 2023 | Freestyle Libre 3 |
| Corcept Therapeutics | $20.65 | 2024 | Korlym |
| Janssen Pharmaceuticals, INC | $18.50 | 2020 | |
| Horizon Therapeutics Plc | $18.31 | 2022 | |
| Ascendis Pharma Endocrinology INC | $16.16 | 2024 | |
| Beta Bionics, INC. | $15.79 | 2024 | Ilet Bionic Pancreas |
| Acella Pharmaceuticals, LLC | $14.57 | 2024 | NP Thyroid 60 |
| Astellas Pharma US INC | $14.22 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marta Terlecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.